Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.56 |
| ▸ | DRD3 | P35462 | 6/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.56 |
| ▸ | HRH1 | P35367 | 5/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.56 |
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172308 | 0.90 | HTR2A (0.54) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL15423265 | 0.87 | HTR2A (0.60) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL15275625 | 0.82 | HTR2A (0.62) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL7168069 | 0.80 | MTNR1A (0.46) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL764376 | 0.79 | HTR1A (0.50) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL764397 | 0.79 | SLC6A4 (0.48) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL13051501 | 0.79 | HTR2A (0.78) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL7168602 | 0.79 | SLC6A2 (0.63) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL10615952 | 0.78 | HTR2A (0.66) | HTR2ASLC6A4SLC6A2CHRM1DRD3 | |
| SCHEMBL7168281 | 0.78 | SLC6A2 (0.64) | HTR2ASLC6A4SLC6A2CHRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2325169-A9 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | University Of Virginia Patent Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2325169-A2 | Lisofylline analogues and their pharmeacuetical uses | University Of Virginia Patent Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| WO-2007027719-A2 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | HTR2A 917/4885SLC6A4 248/4885SLC6A2 575/4885 |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | HTR2A 917/4885SLC6A4 248/4885SLC6A2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.